Released
October 24, 2025
Expires
October 24, 2026
Media Type
Internet
Completion Time
2 hours
Specialties
Cardiology, Critical Care, Emergency Medicine, Neurology, Pharmacy, Primary Care
Topics
Cardiovascular Disease, Heart Disease, Pharmacology, Stroke
Providers/Grant Support
This educational activity is sponsored by Postgraduate Partnerships and supported by an educational grant from Bayer HealthCare Pharmaceuticals, Inc.
Credits Available
- Nurses – 2.0 Contact Hours (1.0 contact hour of pharmacotherapy credit)
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of Registered Nurses and Advanced Practice Registered Nurses.
Program Overview
The goal of this educational activity is to equip and empower primary care and hospital nurses and NPs with the knowledge, competence, and confidence needed to safely and effectively implement FXIa inhibitors for the secondary prevention of non-cardioembolic ischemic stroke when these agents achieve approval thus, leading to optimized outcomes.
Learning Objectives
- Review the epidemiology, patient-centric gravity, and clinical consequences of non-cardioembolic ischemic stroke
- Assess the current standard of care for secondary stroke prevention (SSP) management efficacy and the need to mitigate bleeding risk based on patient specific factors
- Examine the established and evolving evidentiary base for factor XIa inhibitors in non-cardioembolic SSP, highlighting their reduced risk of bleeding
- Apply evidence-based strategies to ensure safe implementation of factor Xia inhibitors into clinical practice
Faculty
Leatrice S. Williams, MN, APRN, ACNS-BC
Clinical Nurse Specialist
Stroke Department
Texas Health Presbyterian Hospital Dallas
Dallas, TX
Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Postgraduate Healthcare Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours. Designated for 1.0 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
Disclosures of Conflict of Interest
Ms. Williams has no actual or potential conflicts of interest in relation to this program.
The clinical reviewer, Brian Cryder, PharmD has no actual or potential conflicts of interest in relation to this program.
Susanne Kwas, MSHF, BSN, RN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
The PIM planners and others have nothing to disclose.
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
Instructions for Participation and Credit
There are no fees for participating and receiving CE credit for this enduring activity. To receive CE credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Pass the posttest with a minimum grade of 70%.
- Complete and submit the evaluation.
A certificate will be immediately available to the participant.
Required Computer Hardware/Software
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac &/ Windows): Microsoft Edge, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, & HTML5
Disclosure of Unlabeled Use and Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, Postgraduate Institute for Medicine (PIM), or Bayer HealthCare Biopharmaceuticals, Inc. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact Postgraduate Institute of Medicine (PIM): [email protected]